



Salud Pública de México

ISSN: 0036-3634

spm@insp.mx

Instituto Nacional de Salud Pública  
México

Aguilar-Salinas, Carlos A; Gómez-Pérez, Francisco J; Rull, Juan; Villalpando, Salvador; Barquera, Simón; Rojas, Rosalba

Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006

Salud Pública de México, vol. 52, núm. 1, 2010, pp. 44-53

Instituto Nacional de Salud Pública

Cuernavaca, México

Available in: <http://www.redalyc.org/articulo.oa?id=10617418008>

- How to cite
- Complete issue
- More information about this article
- Journal's homepage in [redalyc.org](http://redalyc.org)

[redalyc.org](http://redalyc.org)

Scientific Information System

Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal

Non-profit academic project, developed under the open access initiative

# Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006

Carlos A Aguilar-Salinas MC, M Esp,<sup>(1)</sup> Francisco J Gómez-Pérez MC, M Esp,<sup>(1)</sup> Juan Rull, MC, M Esp,<sup>(1)</sup> Salvador Villalpando MC, Dr Sc,<sup>(2)</sup> Simón Barquera MC, PhD,<sup>(2)</sup> Rosalba Rojas MC, PhD<sup>(2)</sup>

Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. *Salud Publica Mex* 2010;52 suppl 1:S44-S53.

Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalencia de las dislipidemias en la Encuesta Nacional de Salud y Nutrición 2006. *Salud Publica Mex* 2010;52 suppl 1:S44-S53.

## Abstract

**Objective.** To describe the prevalence of lipid abnormalities found in the Mexican National Health and Nutrition Survey 2006 (ENSANUT 2006). **Material and Methods.** Information was obtained from 4 040 subjects aged 20 to 69 years, studied after a 9- to 12-hour fast. **Results.** Median lipid concentrations were: cholesterol 198.5 mg/dl, triglycerides 139.6 mg/dl, HDL-cholesterol 39.0 mg/dl, non-HDL-cholesterol 159.5 mg/dl and LDL-cholesterol 131.5 mg/dl. The most frequent abnormality was HDL-cholesterol below 40 mg/dl with a prevalence of 60.5% (95%CI 58.2-62.8%). Hypercholesterolemia ( $\geq 200$  mg/dl) had a frequency of abnormality of 43.6% (95%CI 41.4-46.0%). Only 8.6% of the hypercholesterolemic subjects knew their diagnosis. Hypertriglyceridemia ( $\geq 150$  mg/dl) was observed in 31.5% (IC 95% 29.3-33.9%) of the population. **Conclusions.** The ENSANUT 2006 data confirm that the prevalence of hypoalphalipoproteinemia and other forms of dyslipidemia in Mexican adults is very high.

Key words: cholesterol; triglycerides; cholesterol, HDL; cholesterol, LDL; hypoalphalipoproteinemia; Mexico

## Resumen

**Objetivo.** Presentar la prevalencia de las dislipidemias observada en la Encuesta Nacional de Salud y Nutrición 2006 (ENSANUT 2006). **Material y Métodos.** Se incluyeron 4 040 individuos con edad entre 20 y 69 años estudiados bajo un ayuno de 9 a 12 horas. **Resultados.** Las concentraciones medias de los lípidos sanguíneos fueron colesterol 198.5 mg/dl, triglicéridos 139.6 mg/dl, colesterol HDL 39.0 mg/dl, colesterol noHDL 159.5 mg/dl y colesterol LDL 131.5 mg/dl. La anomalía más común fue la hipoalfalipoproteinemia (colesterol HDL  $< 40$  mg/dl); su prevalencia fue 60.5% (IC 95% 58.2-62.8%). La hipercolesterolemia (colesterol  $\geq 200$  mg/dl) fue la segunda anomalía en frecuencia, con 43.6% (IC 95% 41.4-46.0%). Sólo el 8.6% de los casos conocía su diagnóstico. La hipertrigliceridemia ( $\geq 150$  mg/dl) fue observada en 31.5% (IC 95% 29.3-33.9%) de la población en estudio. **Conclusiones.** Los datos de la ENSANUT 2006 confirman que la prevalencia de hipoalfalipoproteinemia y otras formas de dislipidemia es muy alta en los adultos mexicanos.

Palabras clave: colesterol; triglicéridos; colesterol HDL; colesterol LDL; hipoalfalipoproteinemia; México

(1) Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. México DF, México.

(2) Instituto Nacional de Salud Pública. Cuernavaca, Morelos, México.

Received on: August 5, 2009 • Accepted on: October 2, 2009

Address reprint requests to: PhD. Rosalba Rojas Martínez. Instituto Nacional de Salud Pública. Av. Universidad 655, col Santa María Ahuacatitlán. 62100 Cuernavaca, Morelos, México  
E-mail: rosalba\_rojas@yahoo.com

Chronic non-transmissible diseases are the primary health problem in Mexico, with coronary heart disease and diabetes as the first and second causes of death in Mexico, respectively, followed by stroke.<sup>1</sup> Detection and treatment of lipid disorders are key to the prevention and management of clinical outcomes of chronic non-transmissible diseases. Two nationally representative population-based surveys have shown that lipid abnormalities are the most common cardiovascular risk factors among Mexican adults,<sup>2,3</sup> and hypoalphalipoproteinemia, followed by hypertriglyceridemia, were the abnormalities with the highest prevalence. In addition, 11.7% of Mexican adults have an LDL-cholesterol concentration high enough to qualify for pharmacological treatment.<sup>4</sup> The large percentage of the Mexican population affected by lipid disorders is explained by the interaction of genetic and environmental factors. Risk alleles for having either hypertriglyceridemia or hypoalphalipoproteinemia have a significantly higher frequency among Mexicans compared to other populations.<sup>5</sup> This genetic susceptibility interacts with several environmental factors, such as diets containing large amounts of fat, carbohydrates and calories which are common in this population.<sup>6</sup> Other major contributors include tobacco and alcohol consumption and a sedentary lifestyle. Because the Mexican population is aging,<sup>7</sup> a periodic assessment of the prevalence of cardiovascular risk factors is necessary. This information will help to predict cardiovascular mortality trends for the following years and to design preventive strategies to cope with this health problem.

During 2006, the Ministry of Health of Mexico conducted the National Health and Nutrition Survey, (Encuesta Nacional de Salud y Nutrición, ENSANUT 2006) to estimate the prevalence of obesity, type 2 diabetes, renal pathology, hypertension and dyslipidemia, among many other health conditions. The objective of the report herein is to describe the prevalence of lipid abnormalities in this survey. Results are presented using an epidemiological and a clinically-oriented approach.

## Material and Methods

### Population sample

The objectives and design of the survey have been published elsewhere.<sup>8</sup> In summary, this is a cross-sectional study designed to be representative of individuals living in metropolitan areas (state capitals or cities with a population over 100 000), and urban (population 2 500 to 99 999 inhabitants) and rural settings (less than 2 500 inhabitants). A multistage, stratified probabilistic sampling procedure was used. The country was divided

into four regions (northern, westcentral, central and southern). All of the states in Mexico were included and a random sample of Basic Geographical Statistical Units was obtained in each state. Neighborhood blocks were randomly selected, and for each home, one randomly selected adult, adolescent, infant and health service user was invited to participate. Military, religious, health and other institutions were excluded. A target of 4 731 individuals and 1 476 households was estimated for every state. The sample size was considered to be able to detect risk factors at the state level, with a prevalence of at least 8.1% and a relative error of estimation of 0.25, a design effect of 1.7 and a non-response rate of 20%. The number of households was increased to 1 620 in 13 states to assure enough power to be representative of the communities participating in the *Oportunidades* program. The total number of households was 48 600. This sample size allows for assessing conditions with a prevalence equal to or greater than 0.4%. The study was conducted in accordance with the Helsinki Declaration of Human Studies. Informed consent was obtained from each participant, with a separate consent form signed by participants who provided blood samples. The research and ethics committees of the Instituto Nacional de Salud Pública approved the study protocol.

### Personal interview

A general structured interview was conducted. A previously standardized questionnaire was used to obtain information on demographic and socioeconomic aspects, family health history, personal medical history, and lifestyle factors. During the same visit, anthropometric and blood pressure measurements were obtained. Systolic (1st-phase) and diastolic (5th-phase) blood pressures were measured to the nearest even digit with a sphygmomanometer with the subject in the supine position after a 5-minute rest. Participants removed their shoes and upper garments. Height was measured to the nearest 0.5 cm. Body weight was measured on a scale calibrated daily and recorded to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight (kg) divided by height (m<sup>2</sup>) and was used as an index of overall adiposity. The equipment was regularly calibrated using reference samples provided by the manufacturer.

### Methods

Blood samples were obtained from approximately 30% of the adult population. A random sub-sample of subjects with 8 or more hours of fasting was obtained (n=6 613). This report includes the results of 4 040 subjects who had the 9- to 12-h fasting period required for

a complete lipid profile. These cases were randomly distributed among study subjects. No differences were found between this study's sub-sample and the ENSANUT 2006 population as a whole with regard to age ( $p=0.49$ ), sex ( $p=0.34$ ) and body mass index ( $p=0.59$ ). All analytical measurements were performed at the Instituto Nacional de Salud Pública. The sampling procedure was standardized during a two-week training course. The subjects were sampled at their homes and they remained sitting for five minutes before the blood was drawn.

Total cholesterol was determined using enzymatic hydrolysis and oxidation. Triglycerides concentration was measured after lipase hydrolysis in an automatic analyzer with a tungsten lamp (Prestige 24i, Tokyo Boeki Medical System LTD, Tokyo, Japan). The inter-assay CV was 3.04% for total cholesterol and 5.7% for triglycerides. HDL-cholesterol was measured using an enzymatic colorimetric direct method after eliminating chylomicrons, VLDL, and LDL by enzymatic digestion; the interassay CV was 5.02%. To assure the precision and exactitude of the determinations, concentrations of total cholesterol, HDL-cholesterol and triglycerides were adjusted to a standard curve constructed with the determinations of NIST standard reference materials 909b and 1951b, levels I and II, using a 1:1 dilution. LDL-cholesterol concentration was estimated with the Friedewald formula.<sup>9</sup> Cases with triglycerides above 400 mg/dl were not considered for the estimation of the corresponding LDL-cholesterol values ( $n=39$ ).

### Definitions

Hypertriglyceridemia was defined as a fasting plasma concentration  $\geq 150$  mg/dl. Hypercholesterolemia was defined as a total cholesterol  $\geq 200$  mg/dl. Hypoalphalipoproteinemia was considered present if HDL-cholesterol was  $< 40$  mg/dl. Mixed hyperlipidemia was defined by the presence of cholesterol  $\geq 200$  mg/dl plus triglycerides  $\geq 150$  mg/dl. Normotriglyceridemic hypoalphalipoproteinemia was defined as HDL-cholesterol  $< 40$  mg/dl and triglycerides  $< 150$  mg/dl. These cut points were selected based on National Cholesterol Education Program recommendations.<sup>10</sup> Overweight was defined as BMI 25-30 kg/m<sup>2</sup> and obesity as BMI  $\geq 30$  kg/m<sup>2</sup>. Diabetes was diagnosed if there was a previous medical diagnosis or in the presence of a fasting plasma glucose value  $\geq 126$  mg/dl and no previous history of diabetes. Hypertension was diagnosed when the systolic pressure was  $\geq 140$  mm Hg and/or diastolic pressure was  $\geq 90$  mm Hg and/or current use of antihypertensive medications. Blood pressure was measured twice during two different visits if the initial measurement was  $\geq 120/80$ .

### Statistical analysis

The database was validated through recognition of missing values, outliers and inconsistencies between variables. Due to the characteristics of the survey design, the sample was analyzed as a complex sample using SPSS for Windows version 15. Weights were assigned to correct potential deviations from the age and sex distribution reported in the 2000 population census. Data are presented as medians and 95% confidence intervals (95%CI). Sex-specific estimates were calculated by age group for total cholesterol, HDL-C and triglycerides. The sex-specific prevalence and 95%CI of hypercholesterolemia, hypoalphalipoproteinemia, hypertriglyceridemia, hypertriglyceridemia with hypoalphalipoproteinemia and mixed dyslipidemias were calculated by age and sex groups.

### Results

A total of 4 040 adult cases (1 871 men and 2 169 women) were included in the study. The median age was 40.3 years (95% CI 39.5-40.9). Almost half had an elementary educational level or less (47.9%, 95% CI 44.4-51.5%) while 9.8% (95% CI 7.7-12.4%) had a degree. Median lipid concentrations were: cholesterol 198.5 mg/dl, triglycerides 139.6 mg/dl, HDL-cholesterol 39.0 mg/dl, non-HDL-cholesterol 159.5 mg/dl and LDL-cholesterol 131.5 mg/dl.

Table I shows the median lipid concentration (95%CI) for age and sex groups. After controlling for age, women have higher concentrations of cholesterol, non-HDL-cholesterol and HDL-cholesterol, whereas men had higher triglycerides levels. Differences remained unaltered after controlling for BMI. As expected, a trend for higher cholesterol and triglycerides levels was observed as subjects aged ( $p<0.05$  for all lipid parameters). No significant differences for HDL-cholesterol concentrations were found among age groups.

The medical diagnosis of hypercholesterolemia was done prior to the survey, with a finding of 8.6% (7.2-10.1%); the percentage was less for hypertriglyceridemia (3.8%, 3.0-4.9%). No differences were found between sexes in this regard. Of those with a medical diagnosis of hypercholesterolemia, 71.8% (63.9-78.5%) have received treatment; the percentage was similar for those with the medical diagnosis of hypertriglyceridemia (77.6%, 66.2-86.0%). Drug therapy has been prescribed in a large proportion of treated cases [77.1% (67.8-84.3%) for cases with hypercholesterolemia and 83.6% (71.5-91.2%) for those with hypertriglyceridemia]. Diet was the sole therapy for 21.2% and 16.4% of subjects with hypercholesterolemia and hypertriglyceridemia, respectively.

**Table I**  
**LIPID CONCENTRATIONS OF MEXICAN ADULTS, STRATIFIED BY AGE AND SEX, TRIGLYCERIDES, HDL-CHOLESTEROL, NON-HDL-CHOLESTEROL AND LDL-CHOLESTEROL. MEXICO, ENSANUT 2006**

	Whole population (n=4 040)	Men (n=1 871)	Women (n=2 169)
<b>Cholesterol (mg/dl)</b>			
Total	198.5 (195.6-201.3)	193.3 (189.5-197.1)	202.9 (198.9-206.9)*
20-29	187.5 (182.7-192.4)	184.8 (178.3-191.3)	189.9 (182.6-197.2)
30-39	193.1 (188.3-197.8)	187.9 (180.5-195.3)	197.6 (191.6-203.6)
40-49	204.4 (198.3-210.4)	205.3 (195.3-215.3)	203.6 (196.4-210.8)
50-59	215.6 (207.8-223.4)	201.1 (191.9-210.3)	227.6 (215.7-239.4)*
60 or older	208.9 (201.4-216.5)	198.9 (188.4-209.6)	218.7 (209.6-227.9)*
<b>Triglycerides (mg/dl)</b>			
Total	139.6 (135.7-143.4)	148.9 (142.7-155.1)	131.5 (127.1-135.9)*
20-29	124.8 (117.1-132.6)	135.6 (122.6-148.7)	115.5 (106.8-124.2)
30-39	139.1 (132.9-145.2)	150.1 (140.1-160.1)	129.5 (122.2-136.8)*
40-49	147.1 (138.9-155.3)	161.7 (146.3-177.1)	135.4 (127.9-142.8)*
50-59	164.6 (153.2-176.1)	168.6 (147.8-189.4)	161.4 (149.7-173.0)
60 or older	139.5 (133.0-146.0)	141.1 (130.7-151.4)	137.9 (130.3-145.7)
<b>HDL-cholesterol (mg/dl)</b>			
Total	38.9 (38.4-39.5)	37.1 (36.4-37.8)	40.1 (39.9-41.4)*
20-29	38.5 (37.5-39.4)	36.7 (35.3-37.9)	40.0 (38.9-41.2)*
30-39	38.2 (37.1-39.1)	36.7 (35.3-38.1)	39.4 (38.1-40.7)*
40-49	39.3 (38.3-40.2)	38.4 (36.7-40.1)	39.9 (38.7-41.2)
50-59	40.8 (39.4-42.3)	37.8 (35.8-39.8)	43.3 (41.3-45.3)*
60 or older	39.6 (37.9-41.3)	36.2 (34.4-38.1)	43.0 (40.5-45.4)*
<b>Non-HDL-cholesterol (mg/dl)</b>			
Total	159.5 (156.9-162.0)	156.3 (152.8-159.7)	162.2 (158.7-165.7)
20-29	149.1 (144.7-153.5)	148.1 (142.3-154.0)	149.8 (143.2-156.5)
30-39	154.9 (150.8-159.1)	151.2 (144.7-157.7)	158.2 (152.9-163.5)
40-49	165.1 (159.6-170.5)	166.9 (157.9-175.9)	163.6 (157.2-170.0)
50-59	174.7 (167.9-181.6)	163.3 (155.3-171.3)	184.2 (173.8-194.7)*
60 or older	169.3 (162.8-175.8)	162.7 (153.3-172.1)	175.8 (167.9-183.6)
<b>LDL-cholesterol (mg/dl)</b>			
Total	131.5 (129.1-133.9)	128.1 (124.5-131.6)	136.1 (132.9-139.2)*
20-29	124.8 (120.6-129.0)	122.3 (116.2-128.4)	127.0 (121.1-132.9)
30-39	127.7 (123.6-131.9)	122.6 (115.9-129.3)	132.2 (127.3-137.1)
40-49	136.5 (131.2-141.9)	136.5 (127.2-145.7)	136.6 (130.4-142.8)
50-59	143.8 (137.4-150.1)	133.2 (125.1-141.2)	152.3 (142.8-161.8)*
60 or older	141.9 (135.7-148.1)	135.1 (126.1-144.2)	148.4 (141.0-156.9)

Data are presented as medians (95% CI). \*p<0.05 compared to men

When comparing with previously diagnosed subjects with hypercholesterolemia, median age (49.3 vs. 39.5 years old,  $p<0.001$ ), triglycerides (167.4 vs. 137.1 mg/dl,  $p<0.001$ ), cholesterol (214 vs. 197 mg/dl,  $p<0.01$ ) and non-HDL-cholesterol (174.9 vs. 158 mg/dl,  $p<0.001$ ) concentrations were significantly greater. No differences in plasma lipids levels were found among cases that had received any form of lipid lowering therapy compared to the rest of the population.

### Prevalence of isolated lipid abnormalities

Prevalences for hypertriglyceridemia, hypercholesterolemia and hypoalphalipoproteinemia are shown

in Table II. The most frequent abnormality was hypoalphalipoproteinemia (60.5%, 58.2-62.8%) and the second most frequent abnormality was hypercholesterolemia ( $\geq 200$  mg/dl) (43.6%, 95%CI 41.4-46.0%). Finally, hypertriglyceridemia (triglycerides  $\geq 150$  mg/dl) was found in 31.5% (IC 95% 29.3-33.9%) of the population.

LDL-cholesterol above 130 mg/dl was reported in 41.4% (37.6-45.3%) of men, 50.0% (46.7-53.3%) of women and 46.0% (43.5-48.6%) of the whole population. Non-HDL-cholesterol above 160 mg/dl was present in 39.1% of men (35.3-43.0%), 45.3% of women (42.0-48.6%) and 42.4% of the whole population (39.9-45.0%).

Table II  
PREVALENCE OF LIPID DISORDERS BY AGE AND SEX GROUPS IN MEXICAN ADULTS. MEXICO, ENSANUT 2006

	Whole population (n=4 040)	Men (n=1 871)	Women (n=2 119)
<b>Cholesterol <math>\geq</math> 200 mg/dl</b>			
Total	43.6 (41.4-46.0)	39.3 (35.5-43.3)	47.2 (43.9-50.6)*
20-29	34.8 (30.1-39.9)	33.5 (26.2-41.6)	36.0 (29.9-42.5)
30-39	39.4 (35.1-43.9)	35.6 (28.7-43.3)	42.7 (37.1-48.6)
40-49	50.2 (44.9-55.6)	47.3 (39.1-55.6)	52.6 (45.8-59.4)
50-59	55.2 (49.4-61.0)	43.5 (34.4-53.1)	64.9 (57.5-71.7)*
60 or older	50.6 (44.5-56.6)	44.2 (35.4-53.3)	56.9 (49.4-64.0)
<b>Triglycerides <math>\geq</math> 150 mg/dl</b>			
Total	31.5 (29.3-33.9%)	36.9 (33.0-40.6)	26.9 (24.1-30.0)*
20-29	22.3 (18.2-27.0)	28.9 (21.8-37.2)	16.7 (12.6-21.7)*
30-39	29.6 (25.3-34.4)	38.3 (30.9-46.2)	22.1 (17.7-27.1)*
40-49	37.3 (32.2-42.7)	43.7 (35.8-51.9)	32.2 (25.6-39.7)
50-59	49.1 (43.2-55.1)	48.7 (39.6-57.8)	49.6 (42.2-56.9)
60 or older	31.1 (26.0-36.7)	31.9 (24.5-40.3)	30.3 (23.7-37.8)
<b>HDL-cholesterol <math>&lt;</math> 40 mg/dl</b>			
Total	60.5 (58.2-62.8)	68.1 (64.8-71.2)	54.0 (50.7-57.1)*
20-29	61.9 (56.9-66.7)	68.4 (61.2-74.9)	56.2 (49.8-62.5)
30-39	63.3 (58.8-67.5)	68.4 (60.9-75.0)	58.8 (53.1-64.2)
40-49	60.0 (54.9-64.9)	67.8 (59.9-74.8)	53.8 (46.5-60.9)
50-59	54.1 (47.3-60.6)	65.5 (56.2-73.6)	44.6 (35.8-53.7)*
60 or older	58.9 (53.2-64.4)	69.7 (61.7-76.6)	48.4 (40.9-55.9)*
<b>Non HDL-cholesterol <math>\geq</math> 160 mg/dl</b>			
Total	42.4 (39.9-45.0)	39.1 (35.3-43.0)	45.3 (42.0-48.6)
20-29	33.0 (28.3-38.1)	32.8 (25.6-40.9)	33.1 (27.1-39.8)
30-39	37.4 (33.0-42.1)	34.4 (27.8-41.7)	40.0 (34.5-45.9)
40-49	49.3 (43.8-54.7)	46.4 (38.2-54.8)	51.5 (44.6-58.4)
50-59	55.2 (49.4-60.9)	44.8 (35.8-54.2)	63.8 (56.2-70.7)*
60 or older	51.4 (45.4-57.4)	46.4 (37.6-55.4)	56.3 (48.7-63.5)
<b>LDL-cholesterol <math>\geq</math> 130 mg/dl</b>			
Total	46.0 (43.5-48.6)	41.4 (37.6-45.3)	50.0 (46.7-53.3)*
20-29	39.2 (34.2-44.5)	37.4 (29.9-45.7)	40.7 (34.1-47.7)
30-39	41.4 (37.1-45.9)	36.3 (29.9-43.3)	45.9 (40.1-51.7)
40-49	53.0 (47.5-58.3)	49.4 (41.1-57.7)	55.7 (48.9-62.4)
50-59	53.8 (48.0-59.5)	43.0 (34.2-52.4)	62.5 (54.7-69.7)*
60 or older	53.0 (46.9-59.0)	47.2 (38.4-56.2)	58.5 (51.1-65.6)

Data are presented as percentages (95% CI). \* $p < 0.05$  compared to men

### Sociodemographic characteristics of patients with lipid disorders (Table III)

Environmental factors are major determinants of the prevalence of lipid disorders. For example, hypercholesterolemia was found mainly in metropolitan areas or in subjects living in central or northern Mexico. Its prevalence was not significantly influenced by education level or socioeconomic status, although a trend for a higher prevalence was observed among individuals with medical services provided by ISSSTE (social security and services institute for federal employees)

Hypertriglyceridemia was also more often seen in adults living in metropolitan areas, as well as those living in central Mexico. Its prevalence was also not influenced by education level or socioeconomic status, and it was more common in subjects with access to medical services provided by ISSSTE.

Conversely, low HDL-cholesterol levels were more common in subjects living in rural communities or in southern Mexico. No difference was observed related to education, although a trend for a higher prevalence was observed in lower income groups.



**Table III**  
**SOCIODEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH LIPID DISORDERS. MEXICO, ENSANUT 2006**

		Cholesterol $\geq 200$ mg/dl	Triglycerides $\geq 150$ mg/dl	HDL-C $< 40$ mg/dl
Self reported as native Mexican	Yes	39.3 (34.1-44.7)	35.0 (29.5-40.9)	62.8 (57.2 -68.0)
	No	44.7 (41.9-47.4)	30.8 (28.3-33.4)	60.0 (57.6 -62.4)
Size of locality	Rural (less than 2 500 inhabitants)	35.8 (32.1-39.7)*	27.4 (22.9-32.4)*	61.8 (57.2-66.1)*
	Urban (2 500 to 99 999 inhabitants)	38.9 (34.4-43.7)*	30.6 (26.9-34.5)	68.0 (64.1-71.8)
	Metropolitan area (100 000 and more inhabitants)	48.6 (45.0-52.3)	33.5 (30.2-37.0)	56.5 (53.0-59.8)
Region	North	46.3 (42.4-50.3)‡	29.2 (25.6-33.0)	58.3 (54.4-62.1)‡
	West central	42.1 (36.9-47.6)	28.2 (24.1-32.7)	65.9 (61.2-70.2)‡
	Central	52.1 (46.9-57.2)‡	42.0 (37.0-47.2)‡	49.3 (44.3-54.4)‡
	South	29.8 (26.1-33.8)	22.4 (19.0-26.1)	72.8 (69.2-76.2)
Schooling	Less than elementary	40.5 (33.8-47.6)	28.5 (22.5-35.3)	61.5 (54.5-68.1)
	Elementary	43.9 (40.6-47.3)	32.5 (29.0-36.1)	61.2 (57.5-64.7)
	Secondary	41.3 (36.8-46.0)	30.8 (26.5-35.5)	61.5 (56.9-65.8)
	High school	41.8 (35.9-47.0)	31.1 (25.1-37.8)	57.6 (51.0-63.8)
	More than high school	52.2 (43.1-61.3)	31.9 (24.0-40.9)	59.1 (51.2-66.6)
Socioeconomic status (income deciles)	1 - 2	39.2 (35.7-42.9)	29.6 (26.2-33.2)	63.3 (59.7- 66.8)
	3 - 4	41.9 (36.9-47.1)	32.4 (27.7-37.5)	60.0 (55.0-64.8)
	5 - 7	48.3 (43.6-53.0)	31.6 (27.5-35.9)	59.7 (54.8-64.5)
	8 - 10	49.6 (41.9-57.3)	36.7 (28.9-45.3)	53.7 (45.3-61.8)
Medical service	IMSS	48.1 (43.9-52.3)	32.1 (28.2-36.3)	58.6 (54.2-62.8)
	Seguro Popular	36.0 (30.8-41.6)	27.8 (22.9-33.4)	61.4 (55.6-66.9)
	ISSSTE	55.4 (42.3-67.9)	39.1 (27.2-52.5)	51.0 (38.0-63.9)

Data are presented as percentages (95% CI)

IMSS: Instituto Mexicano del Seguro Social (Mexican Institute of Social Security). ISSSTE: Instituto de Seguridad Social y Servicios para los Trabajadores del Estado (Institute of Social Security and Services for Federal Employees)

\*  $p < 0.05$  compared to the percentage found in the metropolitan areas

‡  $p < 0.05$  compared to the percentage found in the south

### Prevalence of lipid phenotypes (Table IV)

Lipid abnormalities could be due to multiple etiologies and are associated with different cardiovascular risk factors. This is especially true for hypertriglyceridemia. Thus, the crude description of the prevalence of isolated lipid abnormalities is a gross estimation of the lipid-related cardiovascular risk of a population. A more precise description is obtained when the lipid abnormalities are grouped as lipid phenotypes.

The simultaneous elevation of cholesterol and triglycerides concentrations is the lipid profile associated

with the highest atherogenic risk and was observed in 18.2% (95% CI 16.3-20.2%) of the population. Its prevalence increased in direct proportion with age, reaching its maximum in the 40-49 age group. Hypertriglyceridemia/hypoalphalipoproteinemia, also having an atherogenic profile, was observed in 18.3% of the general population; the prevalence was significantly higher in men compared to women ( $p < 0.01$ ). In addition, isolated hypercholesterolemia, which is also associated with an increased cardiovascular risk, was observed in 25.3% of the population. Finally, isolated hypertriglyceridemia was found in 13.3% of study subjects.

Normal concentrations of both cholesterol and triglycerides were found in 43.1% (95% CI 40.7-45.6%) of participants. However, as shown in Table IV, more than 60% of Mexican adults aged 50 or older are at risk of having cardiovascular outcomes based on their cholesterol and/or triglycerides concentrations.

### Lipid abnormalities in cases with excess body weight and type 2 diabetes (Table V)

In our study sample, 1 534 participants were overweight and 1 240 were obese. As shown in Table V, the prevalence of lipid abnormalities was similar between obese

**Table IV**  
**PREVALENCE OF LIPID DISORDERS BY PHENOTYPES IN MEXICAN ADULTS. MEXICO, ENSANUT 2006**

	High TG/ Low HDL-C	Normal TG/ Low HDL-C	High TG/ High Chol	High TG/ Normal Chol	Normal TG/ High Chol	Normal TG/ Normal Chol
Total (n=4 040)	18.3 (16.3-20.5)	42.2 (40.1-44.4)	18.2 (16.3-20.2)	13.3 (11.6-15.2)	25.3 (23.4-27.4)	43.1 (40.7-45.6)
Men (n=1 871)	25.8 (22.5-29.4)	42.3 (38.9-45.8)	18.5 (15.5-22.0)	18.3 (15.3-21.8)	20.8 (18.2-23.7)	42.4 (38.7-46.1)
Women (n=2 169)	11.8 (9.8-14.2)	42.1 (39.3-45.1)	17.9 (15.5-20.7)	9.0 (7.5-10.8)	29.4 (26.4-32.6)	43.7 (40.4-47.0)
Age (years) 20-29	14.9 (11.3-19.5)	47.0 (42.2-51.8)	10.2 (7.3-14.1)	11.8 (8.7-15.7)	23.3 (19.3-27.8)	55.2 (50.0-60.2)
30-39	17.6 (14.1-21.8)	45.6 (41.3-50.0)	13.7 (10.5-17.7)	15.4 (12.0-19.5)	24.6 (21.0-28.6)	46.6 (42.1-51.2)
40-49	21.6 (17.6-26.1)	38.4 (33.3-43.8)	28.5 (22.4-35.5)	22.9 (18.5-28.0)	27.6 (22.8-33.0)	35.7 (31.1-40.5)
50-59	25.6 (19.8-32.2)	28.5 (23.5-34.1)	19.1 (14.6-24.6)	29.2 (23.7-35.3)	26.3 (21.6-31.7)	25.1 (20.5-30.3)
60-69	15.7 (12.0-28.3)	43.2 (37.5-49.1)	9.8 (7.2-13.2)	21.2 (16.6-26.6)	29.7 (25.1-34.8)	39.8 (33.9-46.0)

Data are presented as percentages (95% CI)

**Table V**  
**PLASMA LIPIDS IN THREE BODY MASS INDEX CATEGORIES AND OBESE INDIVIDUALS WITH TYPE 2 DIABETES. MEXICO, ENSANUT 2006**

	BMI < 25 kg/m <sup>2</sup> and no medical diagnosis of diabetes (n=1 182)	BMI 25-29.9 kg/m <sup>2</sup> and no medical diagnosis of diabetes (n=1 337)	BMI >30 kg/m <sup>2</sup> and no medical diagnosis of diabetes (n=1 041)	BMI>30kg/m <sup>2</sup> with medical diagnosis of type 2 diabetes (n=199)
Age (years)	51.6 (46.3-56.8)	56.3 (53.5-59.2)	52.6 (50.2-54.9)	52.6 (49.8-55.4)
Cholesterol (mg/dl)	195.8 (190.4-201.3)	198.3 (194.2-202.5)	198.8 (193.3-204.5)	202.2 (189.6-214.8)
Triglycerides (mg/dl)	116.8 (111.4-122.2)	141.1 (135.4-146.7)	145.0 (138.5-151.5)	163.3 (141.6-185.0)
HDL-cholesterol (mg/dl)	41.1 (39.9-42.2)	38.6 (37.7-39.4)	37.6 (36.7-38.6)	38.1 (35.9-40.1)
Non-HDL-cholesterol (mg/dl)	154.7 (149.8-159.6)	159.7 (155.9-163.3)	161.3 (156.3-166.3)	164.1 (153.1-175.1)
LDL-cholesterol (mg/dl)	131.4 (126.7-136.0)	131.4 (127.7-135.2)	132.3 (127.8-136.8)	131.4 (120.7-142.2)
Cholesterol ≥ 200 mg/dl	41.3 (36.3-46.4)	43.1 (39.0-47.2)	44.3 (39.9-48.7)	48.6 (36.5-60.8)
Triglycerides ≥ 150 mg/dl	18.7 (15.2-22.7)	33.8 (29.6-38.3)	34.6 (30.3-39.1)	43.7 (32.8-55.2)
HDL-C < 40 mg/dl	51.4 (46.8-56.0)	63.9 (59.5-68.0)	62.2 (58.0-66.2)	69.3 (57.9-78.8)
Non HDL-C ≥ 130 mg/dl	68.7 (64.0-73.1)	73.3 (69.8-76.6)	68.1 (64.0-72.1)	74.8 (65.5-82.3)
LDL-C ≥ 100 mg/dl	74.9 (70.2-79.1)	75.6 (71.6-79.3)	72.8 (68.9-76.4)	73.6 (63.6-81.7)
LDL-C ≥ 130 mg/dl	45.1 (40.1-50.3)	44.3 (40.5-48.1)	47.1 (42.8-51.5)	50.4 (38.4-62.3)
High TG/High chol	10.9 (8.4-14.1)	19.4 (16.0-23.3)	20.6 (16.9-24.9)	23.5 (15.8-33.4)
Previous diagnosis of hypercholesterolemia	2.2 (1.2-4.0)	7.0 (5.2-9.2)	12.9 (9.7-17.0)	18.5 (11.4-28.6)
History of receiving any lipid lowering therapy among those previously diagnosed	75.4 (46.3-91.6)	75.9 (64.1-84.8)	67.2 (52.6-79.1)	60.3 (33.9-81.8)

Data are presented as median or percentages (95% CI)



and overweight cases. Hypoalphalipoproteinemia was the most frequent lipid abnormality; its prevalence was significantly higher compared to that found among lean subjects. The prevalence of hypertriglyceridemia was two times higher in individuals with excess body weight compared to the lean group. Excess body weight had no effect on either mean LDL-cholesterol concentration or the prevalence of high LDL-cholesterol levels ( $>130$  mg/dl). Nevertheless, patients with a BMI above  $25 \text{ kg/m}^2$  have a higher prevalence of several atherogenic profiles (i.e. mixed hyperlipidemia).

Type 2 diabetes was present in 488 subjects; 40% were obese. Patients with diabetes and obesity had higher triglycerides and non-HDL-cholesterol concentrations compared to normoglycemic obese individuals, in addition to a higher prevalence of mixed hyperlipidemia. An LDL-cholesterol concentration above  $100 \text{ mg/dl}$  was found in 74.8% (95%CI 72.5-76.9%) of individuals previously diagnosed with diabetes. However, only 7.6% (95%CI 6.3-9.1%) of those were previously diagnosed as having hypercholesterolemia.

## Discussion

Two previous nationally representative population-based surveys<sup>2,3</sup> and several regional studies<sup>11,12</sup> had found that dyslipidemia is the most frequent cardiovascular risk factor in Mexican adults, while the National Health and Nutrition Survey 2006, which expands this information, finds that close to 60% of Mexican adults have hypoalphalipoproteinemia ( $<40 \text{ mg/dl}$ ). In addition, hypercholesterolemia (cholesterol  $\geq 200 \text{ mg/dl}$ ) is present in 43.6% and hypertriglyceridemia (triglycerides  $\geq 150 \text{ mg/dl}$ ) was observed in almost 30% of the population. Several atherogenic lipid phenotypes were frequent in this population, with isolated hypercholesterolemia, mixed hyperlipidemia, and the combination of high triglycerides/low HDL being the most common. The majority of cases remain undiagnosed despite the high prevalence of these conditions. These data will be useful for planning future cardiovascular prevention programs.

Based on the results reported herein, it is estimated that there are 14.8 million Mexican adults with hypercholesterolemia and 10.6 million with hypertriglyceridemia. In addition, 20.5 million have low HDL-cholesterol levels and 6.1 million adults have mixed hyperlipidemia, which is the lipid profile associated with the greatest risk of having cardiovascular events. These numbers summarize the challenge that lipid disorders represent for the Mexican health system.

Dyslipidemias are caused by the interaction of genetic and environmental factors, and Mexicans have

a genetic susceptibility for having abnormal plasma lipids,<sup>5</sup> while Mexican-Americans are the ethnic group living in the US with the highest prevalence of hypoalphalipoproteinemia and hypertriglyceridemia.<sup>13</sup> Several susceptibility alleles for having abnormal concentrations of HDL-cholesterol and triglycerides are common in our population, such as the R230C variant of the ATP-binding cassette transporter A-1<sup>14</sup> and several alleles of the *LIPC*, *CETP*, *MLXIPL*, *LPL* and the *ApoA1-CIII-AIV-AV* genes.<sup>15</sup> In addition, the high consumption of either simple carbohydrates or fat (and alcohol in some groups) and the growing number of adults with a sedentary lifestyle contribute to the high prevalence of hypertriglyceridemia and low HDL-cholesterol. Mexican adults consume a large amount of their calories (a mean of 359) as soft drinks and other sugar-rich beverages.<sup>16</sup> As an expectable result, the prevalence of obesity grew from 23.7% in 2000 to 30.8% in 2006.<sup>7</sup>

The contribution of some environmental factors was also assessed in the report herein. Both hypercholesterolemia and hypertriglyceridemia were found mainly in individuals living in metropolitan areas or in central or northern Mexico. Its prevalence was not influenced by education level or socioeconomic status. Conversely, hypoalphalipoproteinemia was more common in subjects living in rural communities or in southern Mexico; a trend for a higher prevalence was observed in subjects who declare themselves as native Mexicans or in the lowest income stratum.

We expect to find a significant growth in the prevalence of all lipid disorders compared to that found in 1994 and 2000. This hypothesis was true for hypercholesterolemia. Our report confirms the growing trend observed between 1993 and 2000. Mean cholesterol concentrations increased from 182 to  $198.5 \text{ mg/dl}$  between 1993 and 2006. Deterioration of cholesterol concentrations was more severe in women (from 171 to  $202.9 \text{ mg/dl}$ ) compared to men (from 178 to  $193 \text{ mg/dl}$ ). As a result, the prevalence of hypercholesterolemia grew from 27.1% in 1993 to 43.6% in 2006. While an increment was observed in all age groups during this period, the extent of the change was significantly greater in young adults (from 13.9% to 34.8% in the 20-29 age-group) compared to that found in older subjects (from 45.2 to 55.2% for the 50 to 59 age-group). This remarkable change in the prevalence of hypercholesterolemia was seen in both young men (from 17.4 to 33.5% in the age group 20-29) and women (from 11.1 to 36.0%).<sup>17</sup> The trend found in Mexican adults is unlike that seen in the US.<sup>18</sup> Though mean cholesterol levels have decreased in recent years due to the frequent use of statin therapy in older adults,<sup>19</sup> no significant change occurred in the prevalence of low HDL-cholesterol between 1993 and 2006 (61, 63 and

60.5% in the 1993, 2000 and 2006 surveys, respectively). This is in accordance with the strong genetic component of HDL-cholesterol levels.<sup>20</sup> In addition, the components of an unhealthy lifestyle may have mixed effects on HDL-cholesterol levels. For example, the lowering effect of obesity on mean HDL-cholesterol concentrations<sup>21</sup> may be offset by the raising effect of a higher fat intake.<sup>22</sup> Finally, mean triglycerides levels were lower in this survey as compared to previous reports (213 in 1993 vs. 139 mg/dl in 2006). This surprising result may be due to changes in the sampling process that occurred between surveys. For the current study, patients were contacted one day prior to the interview and were asked to have been fasting when the blood sample was scheduled. Interviewers confirmed the fasting conditions of the participants. Since triglycerides values are strongly influenced by the sampling process,<sup>23</sup> we believe that the additional precautions may have influenced the results reported herein.

Data shown in Table V are an example of the well-known deleterious effect of obesity and type 2 diabetes on plasma lipids. Excess body weight (BMI  $\geq 25$  kg/m<sup>2</sup>) is associated with increased concentrations of triglycerides and non-HDL-cholesterol with or without hypoalphalipoproteinemia.<sup>24</sup> Hyperglycemia heightens the severity of these abnormalities and increases the proportion of cases with abnormal plasma lipid levels.<sup>25</sup> Although diabetes is not associated with high LDL-cholesterol levels, a large proportion (74.8%) of previously diagnosed individuals with diabetes had an LDL-cholesterol level above the recommended threshold; and yet, only 7.6% of those were previously diagnosed as having hypercholesterolemia. These observations reinforce the urgent need to train physicians and patients to systematically identify and treat lipid disorders, since this intervention has proved to be cost-effective to reduce the macrovascular complications of type 2 diabetes.<sup>26</sup>

The limitations of the study should be recognized. Differences in analytical methods may limit our ability to make direct comparisons between reports. Also, we were not able to assess the impact of lipid lowering therapies. Regrettably, the questionnaire did not include enough information to assess adherence to therapy.

## Conclusions

Our data confirm that the prevalence of hypoalphalipoproteinemia and other forms of dyslipidemia is high in Mexican adults. Preventive programs are urgently needed in Mexico to face the challenges that lipid disorders represent. Our health and education systems must be redesigned to confront chronic disorders (such as

dyslipidemias) and to reverse the adoption of unhealthy habits. The majority of cases remain undiagnosed despite the high prevalence of these conditions. Primary care physicians should be trained to properly identify and treat such conditions. In addition, the population should be educated to adopt a healthy lifestyle; otherwise, the continuous increase in life expectancy achieved over the past few decades will end in the near future.

## Conflicts of interest

We declare that we have no conflicts of interest.

## References

1. Secretaría de Salud. Subsecretaría de Prevención y Protección de la Salud. Anuarios de Morbilidad 1984-2002. Mexico DF: Secretaría de Salud, 2002.
2. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos JM, Gómez-Pérez FJ, Rull JA, et al. High prevalence of low HDL-cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. *J Lipid Res* 2001;42:1298-1307.
3. Barquera S, Flores M, Olaiz-Fernández G, Monterrubio E, Villalpando S, González C, et al. Dyslipidemias and obesity in Mexico. *Salud Publica Mex* 2007;49 suppl 3:S338-S347.
4. Rojas R, Aguilar-Salinas CA, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, et al. Applicability of the National Cholesterol Education Program III (NCEP-III) Guidelines for treatment of dyslipidemia in a non-Caucasian population: A Mexican Nation-Wide Survey. *Rev Invest Clin* 2005;57:28-37.
5. Aguilar-Salinas CA, Canizales-Quinteros S, Rojas-Martínez R, Mehta R, Villarreal-Molina MT, Arellano-Campos O, et al. Hypoalphalipoproteinemia in populations of Native American ancestry: an opportunity to assess the interaction of genes and the environment. *Curr Opin Lipidol* 2009;20:92-97.
6. Stevens G, Dias RH, Thomas KJA, Rivera JA, Carvalho N, Barquera S, et al. Characterizing the epidemiological transition in Mexico: National and subnational burden of diseases, injuries, and risk factors. *PLoS Med* 5: e125. doi:10.1371/journal.pmed.0050125
7. Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A, Barquera S, Rosas-Peralta M, Hernández-Avila M, et al. Chronic non-communicable diseases in Mexico: epidemiologic synopsis and integral prevention. *Salud Publica Mex* 2008;50:419-427.
8. Barquera S, Campos-Nonato I, Carrión-Rábago C, Villalpando S, López-Ridaura R, Rojas-Martínez R, Aguilar-Salinas C. Methodology for the analysis of type 2 diabetes, metabolic syndrome and cardiovascular disease risk indicators in the ENSANUT 2006. *Salud Publica Mex* 2010;52 suppl 1:S4-S10.
9. Friedewald WT, Levy IR, Fredrickson DS. Estimation of the concentration of low density lipoproteins cholesterol in plasma without the use of the ultracentrifuge. *Clin Chem* 1972; 18:449-502.
10. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA* 2001; 285: 2486-2497.
11. González-Villalpando C, Stern MP, Valdés R, Mitchell B, Haffner S. Niveles de lípidos sanguíneos en población abierta urbana: patrón de riesgo aterogénico elevado. *Rev Invest Clin* 1993; 45: 127-132.
12. González-Villalpando C, Stern MP, Arredondo PB, Martínez DS, Haffner S. Undiagnosed hypercholesterolemia. A serious health challenge. The Mexico City Diabetes Study. *Arch Med Res* 1996; 27:19-23.

13. Palloni A, Morenoff JD. Interpreting the paradoxical in the hispanic paradox: demographic and epidemiologic approaches. *Ann NY Acad Sci* 2001;954:140-174.
14. Villarreal-Molina MT, Aguilar-Salinas CA, Rodríguez-Cruz M, Riaño D, Villalobos-Compan M, Flores-Dorantes MT, et al. The ABCA1 R230C variant affects HDL-cholesterol levels and body mass index in the Mexican population: Association with obesity and obesity-related comorbidities. *Diabetes* 2007;56:1881-1887.
15. Kooner J, Chambers JC, Aguilar-Salinas CA, Hinds DA, Hyde CL, Warnes GR, et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. *Nature Genetics* 2008;40:149-151.
16. Rivera JA, Muñoz-Hernández O, Rosas-Peralta M, Aguilar-Salinas CA, Popkin BM, Willett WC. Beverage consumption for a healthy life: recommendations for the Mexican population. *Rev Invest Clin* 2008;60:157-180.
17. Olaiz-Fernandez G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernández S, Hernández-Avila M, et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, Mexico: Instituto Nacional de Salud Pública, 2006.
18. Carroll MD, Lacher DA, Sorlie PD, Cleeman J, Gordon D, Wolz M, et al. Trends in serum lipids and lipoproteins of adults 1960-2002. *JAMA* 2005;294: 1773-1781.
19. Ford ES, Li C, Zhao C, Mokdad A. Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States. *Circulation* 2009;119:1108-1115.
20. Holleboom AG, Vergeer M, Hovingh K, Kastelein J, Kuivenhoven JA. The value of HDL genetics. *Cur Opin Lipidol* 2008;19:385-394.
21. Merchant AT, Anand SS, Kelemen LE, Vuksan V, Jacobs R, Davis B, et al. Carbohydrate intake and HDL in a multiethnic population. *Am J Clin Nutr* 2007;85:225-230.
22. Mooradian A, Haas M, Wong N. The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I Levels. *Endocrine Reviews* 2006; 27:2-16.
23. Cooper GR, Myers GL, Smith SJ, Schlant RC. Blood lipid measurements. Variations and practical utility. *JAMA* 1992;267:1652-1660.
24. Mittendorfer B, Patterson BW, Klein S, Sidossis S. VLDL-triglyceride kinetics during hyperglycemia/hyperinsulinemia: effects of sex and obesity. *Am J Physiol Endocrinol Metab* 2003; 284: E708-E715.
25. Adiels M, Olofsson S, Taskinen MR, Boren J. Diabetic dyslipidaemia. *Curr Opin Lipidol* 17:238-246.
26. Aguilar-Salinas CA, Mehta R, Rojas R, Gómez-Pérez FJ, Olaiz G, Rull JA. Management of the metabolic syndrome as a strategy for preventing the macrovascular complications of type 2 diabetes: controversial issues. *Current Diabetes Reviews* 2005;1:145-158.